Skip to main content

Guidelines

  • FDA approves Sanofi’s Humalog follow-on Admelog

    The Food and Drug Administration has given full approval to Sanofi’s Admelog short-acting insulin lispro — a follow-on of Eli Lilly’s Humalog. The product received tentative approval from the FDA earlier this year, and now it is the first short-acting follow-on product to get the FDA’s stamp of approval.

  • Greenstone launches authorized Viagra generic

    Pfizer subsidiary Greenstone has introduced its authorized generic of Viagra (sildenafil citrate). The Peapack, N.J.-based company said that its generic would be available in 25-, 50- and 100-mg dosage strengths.

    The erectile dysfunction drug had a market size of roughly $1.4 billion for the 12 months ended August 2017, according to IQVIA data. Greenstone noted that as a Pfizer subsidiary, the company is backed by Pfizer’s distribution and customer service support.

  • Vitamin Packs pitches personalized supplement regimen to Cleveland Clinic conference

    Seattle's Vitamin Packs, the next generation personalized vitamin subscription service, showcased its personalized nutrition capabilities at Dr. Michael Roizen's Preventative, Lifestyle and Integrative Medicine Conference. The conference, held in Las Vegas from Dec. 8 -10, is designed for all medical professionals with an interest in applying preventive, lifestyle and integrative medicine approaches into their practice.  

  • Impax’s Coreg CR generic gets tentative FDA approval

    The Food and Drug Administration has approved specialty pharmaceutical company Impax Labs’ generic of GlaxoSmithKline’s Coreg CR (carvedilol phosphate) extended-release capsules.

  • Flu season begins tracking across the South

    Nationwide, influenza-like activity is beginning to rise for the second week, barely eclipsing the national baseline the Centers for Disease Control and Prevention has established as an indicator that the current flu season is active.

  • CMS reports slowed health spending growth

    The Centers for Medicare and Medicaid Services have released new data from 2016 showing that upward trajectory of U.S. healthcare spending has slowed. The agency, in a report published in the January 2018 issue of Health Affairs that 2016 saw spending increase to 17.9% of U.S. gross domestic product. But that it only grew at a rate of 4.3% — down from the 5.1% and 5.8% spending growth rates seen in 2014 and 2015, respectively.

  • GSK's Shingrix proven effective in immune-compromised patient populations

    GlaxoSmithKline on Wednesday announced that new data from a Phase III clinical study supports the safety and efficacy of Shingrix ((Zoster Vaccine Recombinant, Adjuvanted) in preventing shingles (herpes zoster) when given to adults 18 years and above shortly after undergoing autologous haematopoietic stem cell transplant (auHSCT).

  • Flu illness tracking season officially kicks off with Walgreens' latest Flu Index

    Walgreens on Wednesday launched its first Flu Index for the 2017-18 season. The Flu Index is a weekly report that ranks the top markets and states for flu activity in the U.S., including Puerto Rico.

    Brownsville and Beaumont, Texas are among the top markets for flu this week, and Texas and Arkansas top the list of U.S. states with the most flu activity.

X
This ad will auto-close in 10 seconds